Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2026Reviews in Cardiovascular MedicineOpen Access

Hematuria Management in Patients on Antiplatelet Medications After Acute Coronary Syndrome: A Review of the Current Evidence and Recommendations

View Full Paper
Ask AI
Bookmark
Share

Authors

ILIoannis LoufopoulosKKKonstantinos KapriniotisBFBarbara Fyntanidou

Discussion

Loading...

Member takes

Overview

This review highlights management strategies for hematuria in patients on antiplatelet medications post-ACS, suggesting a multidisciplinary approach.

Key Points

  • To summarize evidence and provide recommendations for managing hematuria in patients receiving antiplatelet therapy after acute coronary syndrome.
  • Review of relevant literature and international guidelines from urology, cardiology, and emergency medicine.
  • Assessment of hemodynamic stability and hematuria severity.
  • Evaluation of antiplatelet therapy modification based on bleeding severity.
  • Discussion of conservative and interventional treatment options.
  • Up to 24% of visible hematuria cases may indicate malignancy.
  • Mild bleeding can allow continuation of dual antiplatelet therapy, while severe cases may require immediate cessation.
  • Interventional measures can range from endoscopic procedures to arterial embolisation, tailored to patient risk.
  • Early resumption of antiplatelet therapy is recommended following an individualized assessment.

Cite This Study

Loufopoulos et al. (2026) studied this question.

synapsesocial.com/papers/69cd7a815652765b073a7b96https://doi.org/10.31083/rcm46334
View Full Paper
Ask AI
Bookmark
Share